Pfizer, one of the world’s largest pharmaceutical companies, has reported better-than-expected financial results thanks to strong sales of its COVID-19 products. According to the company’s latest earnings report, Pfizer’s revenue for the first quarter of 2023 was $14 billion, beating Wall Street estimates of $13.6 billion.

The company’s COVID-19 vaccine, which was developed in partnership with BioNTech, remains one of the most effective and widely used vaccines in the world. Pfizer has shipped over 1 billion doses of the vaccine to more than 100 countries, and continues to work on improving its effectiveness against new variants of the virus.

In addition to its COVID-19 vaccine, Pfizer also produces a number of other COVID-related products, including treatments for the virus and diagnostic tests. The company’s COVID-related products generated over $4 billion in revenue during the first quarter of 2023, helping to offset declines in other areas of the business.

Despite the strong financial results, Pfizer CEO Albert Bourla cautioned that the pandemic is far from over and that the company will continue to focus on developing new treatments and vaccines to combat the virus. “The COVID-19 pandemic continues to pose significant challenges to society and to Pfizer,” Bourla said in a statement. “We remain committed to using our scientific expertise and resources to address this ongoing crisis.”

Overall, Pfizer’s strong performance in the first quarter of 2023 highlights the critical role that pharmaceutical companies have played in the global response to the COVID-19 pandemic. With continued focus and investment in research and development, companies like Pfizer will continue to play a vital role in developing new treatments and vaccines to combat the virus and other global health challenges.